Tag: THERADIAG
COMPLETION OF THE FUSION-ABSORPTION OF THERADIAG BY BIOSYNEX – 12/20/2023 at 6:00 p.m.
Strasbourg and Croissy-Beaubourg, December 15, 2023 – 6:00 p.m. CET – BIOSYNEX and THERADIAG announce that the extraordinary general meetings of shareholders of THERADIAG SA (Euronext Paris: ALTER) and BIOSYNEX…
Completion of the merger absorption of Theradiag by Biosynex
By Hector Chaunu Published on 12/15/2023 at 6:06 p.m. Photo credit © ChaunuPictures (Boursier.com) — BIOSYNEX and THERADIAG…
Biosynex: achievement of Theradiag absorption – 12/15/2023 at 6:28 p.m.
(AOF) – Biosynex and Theradiag announce that their extraordinary general meetings met this Friday and approved the merger-absorption of Theradiag by Biosynex, on the basis of an exchange ratio of…
Biosynex: achieving Theradiag absorption
(AOF) – Biosynex and Theradiag announce that their extraordinary general meetings met this Friday and approved the merger-absorption of Theradiag by Biosynex, on the basis of an exchange ratio of…
Theradiag: growth of 20% in its turnover in the third quarter of 2023
(AOF) – Theradiag posted turnover of 9.9 million euros as of September 30, 2023, up 11% year-on-year. The company specializing in the in vitro diagnosis of autoimmune diseases and Theranostic…
Theradiag: 20% growth in its turnover in the third quarter of 2023 – 10/11/2023 at 6:19 p.m.
(AOF) – Theradiag posted turnover of 9.9 million euros as of September 30, 2023, up 11% year-on-year. The company specializing in the in vitro diagnosis of autoimmune diseases and Theranostic…
Biosynex: Theradiag absorption merger project approved – 09/29/2023 at 6:31 p.m.
(AOF) – The Boards of Directors of Biosynex, specialized in the design, distribution and marketing of in vitro diagnostic devices, and of Theradiag, specialized in in vitro diagnostics, unanimously approved…
Biosynex: Theradiag absorption merger project approved
(AOF) – The Boards of Directors of Biosynex, specialized in the design, distribution and marketing of in vitro diagnostic devices, and of Theradiag, specialized in in vitro diagnostics, unanimously approved…
Theradiag announces an improvement in its results in the first half – 09/18/2023 at 10:24 a.m.
(AOF) – Theradiag announces a net result of 853,000 euros in the first half, compared to a net loss of 56,000 euros a year ago. The in vitro diagnostics specialist…
Theradiag announces an improvement in its results in the first half
(AOF) – Theradiag announces a net result of 853,000 euros in the first half, compared to a net loss of 56,000 euros a year ago. The in vitro diagnostics specialist…
Theradiag: improved profitability in the first half – 09/18/2023 at 12:27
(CercleFinance.com) – Theradiag, a specialist in in vitro diagnostics, rose by more than 2% this Monday on the Paris Stock Exchange following the publication of first half results showing a…
Theradiag: Improved profitability in the first half
Read also (CercleFinance.com) – Theradiag, a specialist in in vitro diagnostics, rose by more than 2% this Monday on the Paris Stock Exchange following the publication of first half results…